 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Adit Ginde and Toan Ong.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.745 |
|
|
|
-
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele J, Wogu AF, Wynia MK, Zane RD, Ginde AA. Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. J Infect Dis. 2022 12 13; 226(12):2129-2136.
Score: 0.210
-
Douin DJ, Wogu AF, Beaty LE, Carlson NE, Bennett TD, Aggarwal NR, Mayer DA, Ong TC, Russell S, Steele J, Peers JL, Molina KC, Wynia MK, Ginde AA. Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients. BMC Infect Dis. 2022 Nov 07; 22(1):818.
Score: 0.209
-
Wynia MK, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, Mayer DA, Ong TC, Russell S, Steele JD, Stocker HR, Wogu AF, Zane RD, Sokol RJ, Ginde AA. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Chest. 2023 05; 163(5):1061-1070.
Score: 0.208
-
Link-Gelles R, Chickery S, Webber A, Ong TC, Rowley EAK, DeSilva MB, Dascomb K, Irving SA, Klein NP, Grannis SJ, Barron MA, Reese SE, McEvoy C, Sheffield T, Naleway AL, Zerbo O, Rogerson C, Self WH, Zhu Y, Lauring AS, Martin ET, Peltan ID, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Prekker ME, Mohamed A, Johnson N, Steingrub JS, Khan A, Felzer JR, Duggal A, Wilson JG, Qadir N, Mallow C, Kwon JH, Columbus C, Vaughn IA, Safdar B, Mosier JM, Harris ES, Chappell JD, Halasa N, Johnson C, Natarajan K, Lewis NM, Ellington S, Reeves EL, DeCuir J, McMorrow M, Paden CR, Payne AB, Dawood FS, Surie D. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged =18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):73-82.
Score: 0.061
-
DeCuir J, Payne AB, Self WH, Rowley EAK, Dascomb K, DeSilva MB, Irving SA, Grannis SJ, Ong TC, Klein NP, Weber ZA, Reese SE, Ball SW, Barron MA, Naleway AL, Dixon BE, Essien I, Bride D, Natarajan K, Fireman B, Shah AB, Okwuazi E, Wiegand R, Zhu Y, Lauring AS, Martin ET, Gaglani M, Peltan ID, Brown SM, Ginde AA, Mohr NM, Gibbs KW, Hager DN, Prekker M, Mohamed A, Srinivasan V, Steingrub JS, Khan A, Busse LW, Duggal A, Wilson JG, Chang SY, Mallow C, Kwon JH, Exline MC, Columbus C, Vaughn IA, Safdar B, Mosier JM, Harris ES, Casey JD, Chappell JD, Grijalva CG, Swan SA, Johnson C, Lewis NM, Ellington S, Adams K, Tenforde MW, Paden CR, Dawood FS, Fleming-Dutra KE, Surie D, Link-Gelles R. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged =18 Years - VISION and IVY Networks, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):180-188.
Score: 0.057
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|